Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.37 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7266955 | 0.77 | TDP1 (0.54) | LMNATDP1ALDH1A1CNR2EGFR | |
| SCHEMBL10697322 | 0.76 | MCL1 (0.53) | TDP1MCL1ALDH1A1MEN1KMT2A | |
| SCHEMBL15660997 | 0.74 | NAAA (0.52) | LMNATDP1ALDH1A1EGFR | |
| SCHEMBL5326403 | 0.73 | CA1 (0.48) | CA1ACE2 | |
| SCHEMBL5319436 | 0.73 | ALDH1A1 (0.50) | LMNATDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL9112486 | 0.72 | EGFR (0.56) | LMNATDP1ALDH1A1EGFRKMT2A | |
| SCHEMBL9111066 | 0.72 | EGFR (0.56) | LMNATDP1ALDH1A1EGFRKMT2A | |
| SCHEMBL83536 | 0.72 | TDP1 (0.49) | LMNATDP1ALDH1A1CNR2EGFR | |
| Arundic Acid SCHEMBL5010029 | 0.72 | TDP1 (0.46) | LMNATDP1ALDH1A1EGFRMEN1 | |
| SCHEMBL2727700 | 0.72 | TDP1 (0.59) | LMNATDP1EGFRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293535-A1 | ERBB/BTK INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| EP-3205650-A1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2017-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293535-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | LMNA 4868/4885TDP1 2118/4885MCL1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.